Paxlovid may help some long COVID patients: Research

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long COVID when administered outside of an infection.

Administration of Paxlovid during a SARS-CoV-2 infection has previously been linked to a lower risk of developing long COVID symptoms. But a study published in the Nature science journal suggests taking the treatment may have benefits for people with long COVID when they're not experiencing an active infection.

Paxlovid is recommended for use within five days of COVID-19 symptoms when someone tests positive for the virus. The treatment is a round of two drugs — two nirmatrelvir pills and one ritonavir pill — that are taken twice daily for five days.

The patient-led research collaborative that worked on the study looked at 13 people diagnosed with long COVID who took rounds of Paxlovid lasting longer than five days. The participants had infections stemming from COVID-19 variants like the original strain from 2020, the delta variant and the omicron variant.

The participants took Paxlovid from seven-and-a-half days to 30 days. The group included people who had COVID-19 infections between 2020 to 2023.

Of the 13 participants, seven said they experienced an improvement in their long COVID symptoms and five of those participants said they experienced sustained improvement.

One 56-year-old male participant who was infected in 2020 with the original strain of COVID-19 first completed a standard five-day course of Paxlovid in September 2022 with no improvement in his long COVID symptoms.

But after taking an extended 15-day course of Paxlovid in December, the participant reported improvements in his neurocognitive symptoms. One week after completing his treatment, he reported an "almost complete resolution" of his symptoms.

The authors of the study acknowledged the limitations of their analysis.

"First, while this study is large for a case series, it is still only reporting on the experiences of 13 individuals, who may or may not be representative of the experiences of all patients with Long COVID," they wrote. They also noted that the participants were all people with enough "technological savvy to communicate over the internet or phone" and spoke English proficiently.

The study was also self-reported by patients, leaving room for recall bias or fatigue bias. But the study authors also pointed to its strengths, including its novelty and capture of data that may have been missed by traditional medical records.

"While the case series findings are heterogeneous, we describe the use of long courses of Paxlovid as a potentially promising pharmaceutical treatment to support at least some people with Long COVID," wrote the researchers. "These cases provide strong rationale for the ongoing study of antivirals for Long COVID to determine if, when, and how they should be used in this patient population."

One of the authors, Micharl Perluso, reported one conflict of interest as he has served as a consultant for Gilead Sciences and AstraZeneca, competitors of Paxlovid's manufacturer Pfizer.

Topics

Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report

But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who benefited said the improvement didn’t last.
The New York Times - 1d
A&E patients facing two-day waits in Liverpool

Patients in A&E at the Royal Liverpool University Hospital are facing waits of up to 50 hours.
BBC News - 8h
Ambulance handover delays in England may harm 1,000 patients a day

Exclusive: 414,137 people believed to have experienced some level of harm in last year, Guardian analysis finds. More than 1,000 patients a day in England are suffering “potential harm” because of ...
The Guardian - 2d
German interior minister: Some Syrians in Germany may have to return

Yahoo News - 2d
Possible Tariff Effects May Dim Some Buzz at CES

Auto and tech exhibitors at the massive trade show that runs in Las Vegas from Jan. 7-10 will have to factor in the impact of Trump’s promised import levies as they try to grab headlines for new ...
Inc. - 4d
Why law enforcement thinks New Orleans truck attacker may have had help

The FBI says the driver is not believed to be "solely responsible" for the early New Year's Day truck attack on New Orleans' Bourbon Street. CBS News' Samantha Vinograd and Nicole Sganga have more.
CBS News - 6d
Quitting smoking may be easier with a smartwatch app, researchers say

Motion-sensor software sent alerts to prevent lighting up at most vulnerable moments for those trying to quit. Smartwatches could be used to help people quit smoking, a study suggests.. Researchers ...
The Guardian - 6d